Illumina, Inc. $ILMN Stock Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 21.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 746,778 shares of the life sciences company's stock after selling 203,293 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.49% of Illumina worth $204,378,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in shares of Illumina in the 2nd quarter valued at about $3,374,423,000. WCM Investment Management LLC boosted its stake in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the period. Primecap Management Co. CA purchased a new position in Illumina during the 2nd quarter worth $617,981,000. Janus Henderson Group PLC raised its holdings in shares of Illumina by 1.4% in the first quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company's stock valued at $258,924,000 after buying an additional 29,094 shares during the last quarter. Finally, Southpoint Capital Advisors LP grew its holdings in shares of Illumina by 20.0% during the first quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company's stock worth $258,846,000 after buying an additional 349,536 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ILMN shares. Sanford C. Bernstein reissued a "market perform" rating and issued a $215.00 target price on shares of Illumina in a report on Friday, July 31st. Stifel Nicolaus boosted their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a "buy" rating in a research note on Friday, July 31st. TD Cowen raised their target price on shares of Illumina from $210.00 to $270.00 and gave the stock a "hold" rating in a research note on Tuesday, October 13th. Royal Bank Of Canada lifted their target price on shares of Illumina from $230.00 to $310.00 and gave the company an "outperform" rating in a report on Monday, October 5th. Finally, Stephens cut shares of Illumina from an "overweight" rating to an "equal weight" rating and set a $275.00 price target for the company. in a report on Friday, October 23rd. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, Illumina currently has an average rating of "Hold" and a consensus price target of $238.53.

Insider Activity

In related news, Director Keith Meister sold 457,858 shares of the business's stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the sale, the director directly owned 2,372,694 shares in the company, valued at $474,776,069.40. The trade was a 16.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 2,061,235 shares of company stock worth $436,356,102. Insiders own 2.90% of the company's stock.

Illumina Price Performance

ILMN stock opened at $235.99 on Monday. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57. The company's 50-day moving average price is $249.30 and its 200 day moving average price is $176.18. Illumina, Inc. has a 52 week low of $106.12 and a 52 week high of $309.35. The company has a market cap of $35.63 billion, a P/E ratio of 40.62, a P/E/G ratio of 3.30 and a beta of 1.46.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.26. The company had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the firm earned $1.34 EPS. On average, research analysts expect that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.